Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020181140 - CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS

Publication Number WO/2020/181140
Publication Date 10.09.2020
International Application No. PCT/US2020/021270
International Filing Date 05.03.2020
IPC
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
C07K 16/18 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
C07K 16/2809
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
2809against the T-cell receptor (TcR)-CD3 complex
C07K 16/2827
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
2827against B7 molecules, e.g. CD80, CD86
C07K 16/2863
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2863against receptors for growth factors, growth regulators
C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Applicants
  • MAVERICK THERAPEUTICS, INC. [US]/[US]
  • MAY, Chad [US]/[US]
  • DUBRIDGE, Robert, B. [US]/[US]
  • VINOGRADOVA, Maia [US]/[US]
  • PANCHAL, Anand [IN]/[US]
Inventors
  • MAY, Chad
  • DUBRIDGE, Robert, B.
  • VINOGRADOVA, Maia
  • PANCHAL, Anand
Agents
  • SILVA, Robin, M.
  • ESKER, Todd, W.
  • GE, Xinquan
  • BALL, Conor, S.
  • ANTCZAK, Andrew
Priority Data
62/814,21005.03.2019US
62/814,74406.03.2019US
62/826,52329.03.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
(FR) PROTÉINES DE LIAISON À ACTIVATION CONDITIONNELLE LIMITÉE
Abstract
(EN)
The invention relates to Conditional Bispedfic Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen is B7H3.
(FR)
L'invention concerne des constructions d'activation redirigées bispécifiques conditionnelles, ou COBRA, qui sont administrées dans un format de pro-médicament actif. Lors de l'exposition à des protéases tumorales, les constructions sont clivées et activées, de telle sorte qu'elles peuvent se lier à la fois à des antigènes cibles tumoraux (TTA) ainsi que des CD3, recrutant ainsi des lymphocytes T exprimant CD3 sur la tumeur, ce qui conduit à un traitement. Dans certains modes de réalisation, l'antigène cible tumoral est B7H3.
Latest bibliographic data on file with the International Bureau